Results 21 to 30 of about 13,155 (273)
Proteolysis Targeting Chimera Degraders of the METTL3–14 m6A‑RNA Methyltransferase [PDF]
JACS AuFrancesco Errani +9 more
doaj +2 more sources
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Molecular Cancer, 2022 AbstractProteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits target protein and E3 ubiquitin ligase together to trigger proteasomal degradation of target protein by the ubiquitin-proteasome system. PROTAC has emerged as a promising
Xinyi Li +5 more
openaire +3 more sources
Molecules, 2022 Viral infections pose a persistent threat to human health. The relentless epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health problem, with millions of infections and fatalities so far.
Shujing Xu +7 more
doaj +1 more source
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Nature Communications, 2022 SMARCA2 has been identified as a synthetic lethal target in SMARCA4 mutated tumors, however, homology between the two has hindered the development of selective SMARCA2 inhibitors.
Jennifer Cantley +28 more
doaj +1 more source
Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
Frontiers in Chemistry, 2021 Photopharmacology is an emerging field that uses light to precisely control drug activity. This strategy promises to improve drug specificity for reducing off-target effects.
Shenxin Zeng +7 more
doaj +1 more source
Proteolysis targeting chimeras (PROTACs) in cancer therapy [PDF]
Journal of Experimental & Clinical Cancer Research, 2020 AbstractExploitation of the protein degradation machinery as a therapeutic strategy to degrade oncogenic proteins is experiencing revolutionary advances with the development of proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional structures consisting of a ligand that binds a protein to be degraded and a ligand for an E3 ubiquitin ...
Alberto Ocaña, Atanasio Pandiella
openaire +5 more sources
Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras
Molecules, 2023 α-Synuclein aggregation under pathological conditions is one of the causes of related neurodegenerative diseases. PROTACs (proteolysis targeting chimeras) are bifunctional small molecules that induce a post-translational erasure of proteins via the ...
Tianzhi Wen +3 more
doaj +1 more source
Frontiers in Oncology, 2023 Enhancer of zeste homolog 2 (EZH2) and Bruton’s tyrosine kinase (BTK) are both key factors involved in the development and progression of hematological malignancies.
Yurim Jeong +7 more
doaj +1 more source
Proteolysis Targeting Chimeras (PROTACs)
ACS Pharmacology and Translational Science, 2022 Targeted protein degradation (TPD) is a promising therapeutic modality to modulate protein levels and its application promises to reduce the "undruggable"proteome. Among TPD strategies, Proteolysis TArgeting Chimera (PROTAC) technology has shown a tremendous potential with attractive advantages when compared to the inhibition of the same target.
Ruffilli, Camilla +5 more
openaire +1 more source
Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders [PDF]
Future Medicinal Chemistry, 2020 Targeted protein degradation by small-molecule degraders represents an emerging mode of action in drug discovery. Proteolysis targeting chimeras (PROTACs) are small molecules that can recruit an E3 ligase and a protein of interest (POI) into proximity, leading to induced ubiquitination and degradation of the POI by the proteasome system.
Xingui Liu +5 more
openaire +2 more sources